News and Media

📢 Product Launch Announcement: Pregaforce 150 We are excited to announce the launch of Pregaforce 150, a high-strength formulation of Pregabalin 150 mg, designed to meet the demanding needs of neurological care.Pregaforce 150 offers proven effectiveness in managing neuropathic pain, partial onset seizures, and related neurological disorders, delivering fast-acting and sustained relief to improve patients’…

📢 Product Launch Announcement: Pregaforce 75 We are proud to announce the launch of Pregaforce 75, a clinically proven formulation of Pregabalin 75 mg, designed to offer effective and sustained neurological care. Pregaforce 75 provides reliable relief for patients suffering from neuropathic pain, epilepsy, and generalized anxiety disorder, improving both clinical outcomes and overall quality…

📢 Product Launch Announcement: Dutafree 0.5 We are proud to introduce Dutafree 0.5, a scientifically advanced formulation of Dutasteride 0.5 mg, developed to offer effective and sustained relief from the symptoms of Benign Prostatic Hyperplasia (BPH).With Dutafree 0.5, physicians and patients now have access to a trusted solution that targets the root causes of prostate…

📢 Product Launch Announcement: Ondoforce MD 8 We are proud to introduce Ondoforce MD 8, a clinically advanced, orally disintegrating formulation of Ondansetron 8 mg, developed to provide rapid and effective control of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery. With its fast-dissolving technology and powerful anti-emetic action, Ondoforce MD 8 delivers…

📢 Product Launch Announcement: Ondoforce MD 4 We are proud to announce the launch of Ondoforce MD 4, an advanced orally disintegrating formulation of Ondansetron 4 mg, specifically designed for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery. Ondoforce MD 4 combines clinical reliability with patient-friendly innovation, offering…

📢 Product Launch Announcement: Modatime 200 We are excited to announce the launch of Modatime 200, a high-quality formulation of Modafinil 200 mg, designed to improve wakefulness in individuals suffering from narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD). Modatime 200 is a trusted solution for healthcare providers and patients seeking a…

📢 Product Launch Announcement: Minoxymax 5 We are proud to introduce Minoxymax 5, an innovative oral solution containing Minoxidil 5 mg, developed to effectively address male and female pattern hair loss. Minoxymax 5 offers a scientifically proven, convenient, and powerful approach for doctors, hospitals, and patients seeking clinically effective hair regrowth solutions. 🔹 About Minoxymax…

📢 Product Launch Announcement: Minoxymax 2.5 We are proud to announce the launch of Minoxymax 2.5, a breakthrough in oral therapy for male and female pattern hair loss, offering patients and healthcare providers an effective and convenient alternative to traditional topical treatments. Minoxymax 2.5 brings together clinical innovation and trusted care, empowering doctors, hospitals, and…

📢 Product Launch Announcement: Iverclear 6 We are pleased to announce the launch of Iverclear 6, our advanced formulation of Ivermectin 6 mg, developed to offer effective, reliable, and convenient treatment for a broad range of worm infections and parasitic diseases. With a strong foundation in clinical research and global therapeutic experience, Iverclear 6 embodies…

📢 Product Launch Announcement: Hairpecia 1 We are proud to announce the launch of Hairpecia 1, a clinically trusted formulation of Finasteride 1 mg, specially developed to combat male pattern hair loss and restore self-confidence. Hairpecia 1 represents a significant advancement in the management of androgenetic alopecia, offering doctors, hospitals, and patients a highly effective,…